Estimating burden of cardiovascular disease among survivors of breast, colorectal, lung, and prostate cancer in the detroit research on cancer survivors (ROCS) cohort.
Vidhya Nair(University Health Network), Jennifer Lynn Beebe-Dimmer(Wayne State University), Ana Barac(Inova Fairfax Hospital), Kerryn W. Reding(University of Washington), Michael S. Simon(Exponent (United States)), Alexi Vasbinder(University of Washington), Julie J. Ruterbusch(Wayne State University), Sreejata Raychaudhuri(UPMC Hillman Cancer Center), Richard K. Cheng(University of Washington)
Cited by 0
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2017|1.3k
Cardiac tumours: diagnosis and management
|The Lancet Oncology|2005|848
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Somatic mutations precede acute myeloid leukemia years before diagnosis
|Nature Medicine|2018|621